Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark C M, Lee V M
Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Japan.
Ann Neurol. 1995 Oct;38(4):649-52. doi: 10.1002/ana.410380414.
Cerebrospinal fluid from 70 patients with Alzheimer's disease (AD) and 96 patients with non-AD neurological diseases as well as 19 normal control subjects was surveyed by sandwich enzyme-linked immunosorbent assay to quantitate levels of the microtubule-associated protein tau in cerebrospinal fluid. The tau level was significantly increased in AD patients as compared with that in patients with non-AD neurological diseases and control subjects. Increased tau levels were found irrespective of age at onset, apolipoprotein E genotype, and clinical stage. Western blots of AD cerebrospinal fluid proteins revealed two to three tau-immunoreactive bands with an apparent molecular mass between 50 and 65 kd consistent with phosphorylated cerebrospinal fluid tau. Taken together, our results suggest that cerebrospinal fluid tau might reflect the progressive accumulation of altered tau due to the progressive death of neurons in the AD brain, and that the enzyme-linked immunosorbent assay of cerebrospinal fluid tau may prove to be a reliable and early diagnostic test for AD.
采用夹心酶联免疫吸附测定法对70例阿尔茨海默病（AD）患者、96例非AD神经疾病患者以及19名正常对照者的脑脊液进行检测，以定量测定脑脊液中微管相关蛋白tau的水平。与非AD神经疾病患者和对照者相比，AD患者的tau水平显著升高。无论发病年龄、载脂蛋白E基因型和临床分期如何，均发现tau水平升高。对AD患者脑脊液蛋白进行的蛋白质免疫印迹分析显示，有两到三条tau免疫反应带，其表观分子量在50至65kd之间，与磷酸化脑脊液tau一致。综合来看，我们的结果表明，脑脊液tau可能反映了AD大脑中神经元逐渐死亡导致的tau改变的渐进性积累，并且脑脊液tau的酶联免疫吸附测定可能被证明是一种可靠的AD早期诊断检测方法。
